CSA Medical expands truFreeze label


CSA Medical, Inc. has expanded its truFreeze label with the addition of Barrett’s Esophagus (BE) with low-grade dysplasia.

CSA Medical develops and manufactures a proprietary interventional spray cryotherapy technology platform utilising unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing.

The expansion of the truFreeze label comes after the submission of clinical data supporting the use of truFreeze Spray Cryotherapy in patients with BE and low-grade dysplasia. The Food and Drug Administration (FDA) has now recognised the safety and effectiveness of the trueFreeze system.

... to continue reading you must be subscribed

Subscribe Today

Paywall Asset Header Graphic

To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.

Please wait...